- Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
-
Viljoen A, Bain SC
- KMID: 2539814
- Endocrinol Metab.
- 2023 Feb;38(1):25-33.
- doi: 10.3803/EnM.2022.1642
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness... -
- CITED
-
- Close
- SHARE
-
- Close
